AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04836286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotive Intelligent Spaces (EIS)
Description: The EIS leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study11, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
Study NCT05816681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1230
Description: Daewoong Pharmaceutical
Study NCT05816681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWB2001
Description: Daewoong Bio
Study NCT05800990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Research participants will be assigned to two dietary conditions.
Study NCT06157424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of proton pump inhibitors, additional antacids as needed, and lifestyle modifications.
Study NCT05609227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: The application, compatible with IOS and android systems for patients candidate for stem cell transplantation, could be applied whenever needed information relating to transplantation process.
Study NCT05837754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C8-C12
Description: 5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
Study NCT05997589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive educational materials
Study NCT05997589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend financial health educational program
Study NCT05997589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05911568 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular Stroke Treatment
Description: Patients who receive endovascular stroke treatment when they are admitted into the hospital, as determined by their clinical care team. Endovascular stroke treatment consist of catheter-based treatment for the blood clot causing the acute ischemic stroke
Study NCT05911568 — intervention group
Intervention type: OTHER
Intervention: Medical Management
Description: Patients who receive MMM when they are admitted into the hospital, as determined by their clinical care team. MMM may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care. Specifically, this treatment does not involve endovascular stroke treatment.
Study NCT05837754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
Study NCT06093802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Drug-induced Sleep Endoscopy findings (identified obstruction sites)
Description: As described above
Study NCT06093802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Drug-induced Sleep Endoscopy findings (identified obstruction sites)
Description: As described above
Study NCT05369390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111 A
Description: Participants will receive NNC0487-0111 A tablet once daily.
Study NCT05505422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine ECMO
Description: Routine ECMO during lung tansplant
Study NCT05369390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111 B
Description: Participants will receive NNC0487-0111 B tablet once daily.
Study NCT05369390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo B (NNC0487-0111 B)
Description: Participants will receive placebo matched to NNC0487-0111 B tablet once daily.
Study NCT05369390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo A (NNC0487-0111 A)
Description: Participants will receive placebo matched to NNC0487-0111 A tablet once daily.
Study NCT05505422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On demand ECMO
Description: Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~1. Inability to maintain adequate hemodynamics and stable perfusion or oxygenation during surgery~2. Prolonged high dose pressor required to maintain adequate perfusion~3. A sustained drop in cerebral saturation > 25% of baseline despite initial attempts at optimization~4. Inability to tolerate pulmonary artery clamping~5. Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~6. Inadequate exposure to the surgical field
Study NCT05445193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEaters Choice Module
Description: There will be nine sessions conducted throughout the intervention period, which include module activity, assessment sessions and follow-up sessions. This module will have four primary sub modules (SM): SM1- An overview of picky eaters, SM2-Healthy eating for children, SM3-Parental Strategies and SM4- Sensory perception.
Study NCT05440825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRelax
Description: Virtual Relaxation relaxation, VRelax, includes a collection of high quality 360° degrees videos of nature environments with 3D audio and interactive elements, created for relaxation, stress-reduction and improving sleep. When activated, the participant can choose specific 360° videos from a menu. The 360° videos include among other things a coral reef with an interactive game element of popping air bubbles, a scuba diving experience with dolphins, a mountain meadow with cows, and a session of Tibetan sound bowls.
Study NCT05440825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation exercises
Description: Relaxation exercises consisting of audio-guided breathing exercises, muscle relaxation exercises, and body scan exercises
Study NCT04697225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss strategies
Description: Participants will receive recommendations on how to increase physical activity, decrease caloric intake, monitor their weight, and track the related behaviors and progress.
Study NCT04697225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss coaching sessions and email support
Description: Participants will receive weekly coaching sessions and tailored support emails.
Study NCT06137352 — intervention group
Intervention type: OTHER
Intervention: Follow up
Description: Each subject was recruited in 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and followed up at 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, with a total of two follow-up visits. At enrollment and both follow-up visits, subjects were required to collect 2 tubes of peripheral venous blood each.
Study NCT05531240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate Artery Embolization
Description: Prostate Artery Embolization (PAE) is performed by experienced interventional radiologists. The method involves catheterization of the prostate vessels superselectively with two to three French microcatheters. PAE is performed with microspheres of 250 to 400 µm in size.
Study NCT05531240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Prostate Resection (TURP)
Description: Under general/regional anesthesia, a resectoscope is inserted into the urethra that carries an electric metal loop (monopolar or bipolar diathermy) that is used to cut and extract the prostate tissue.
Study NCT05496010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling and Ischemic Compression Technique
Description: For Group A, Dry needling will be applied into trigger points which are active and present in the muscles, efficiently and within the safe limits taking all the safety precautions.~For group B, Ischemic Compression Technique will be applied on trigger points.~The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved for both the groups.
Study NCT05496010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling and Ischemic Compression Technique
Description: For Group A, Dry needling will be applied into trigger points which are active and present in the muscles, efficiently and within the safe limits taking all the safety precautions.~For group B, Ischemic Compression Technique will be applied on trigger points.~The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved for both the groups.
Study NCT04816253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline irrigation and No other drug placed after extraction
Study NCT04816253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
Study NCT04816253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednsolone will be injected half an hour preoperatively
Study NCT04816253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone and Hyaluronic acid
Description: Methylprednisolone will be injected half an hour preoperatively and Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
Study NCT04891120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treadmill test (Bruce protocol)
Description: Treadmill test performed with and without a mask.
Study NCT05087745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study NCT05641961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship mobile application
Description: Mobile phone application
Study NCT05641961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires assessing cancer knowledge and system usability will be delivered to participants via Survivorship App
Study NCT05223101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telminone 80 mg
Description: Single administration of telmisartan 80 mg
Study NCT04029844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colibri TAVI System
Description: Implantation of Colibri heart valve
Study NCT06521450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anti incontinence surgery
Description: anti incontinence surgery with prolapse surgery will be performed simultaneously
Study NCT05194566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tACS
Description: Neurostimulation will be done using the Neuro Device tCS (Neuro Device tCS), which is a certified transcranial electrical stimulator. The device consists of a stimulator with a touch screen, two electrodes and a soft, flexible cap to ensure stability of the electrodes on the head.
Study NCT05194566 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS
Description: Neurostimulation will be done using the Neuro Device tCS (Neuro Device tCS), which is a certified transcranial electrical stimulator. The device consists of a stimulator with a touch screen, two electrodes and a soft, flexible cap to ensure stability of the electrodes on the head.
Study NCT04772742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - solution for infusion
Study NCT04772742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab - 100 mg, solution for infusion
Study NCT04772742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eptinezumab
Description: Eptinezumab - 100 mg, solution for infusion
Study NCT06054204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lateral bony window
Description: bony window will be made on lateral maxillary sinus wall using piezo-electric device after elevation of full thickness mucoperiosteal membrane
Study NCT05223101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Micardis 80 mg
Description: Single administration of telmisartan 80 mg
Study NCT05418712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-150 for oral administration.
Study NCT05418712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Solution or Suspension for oral administration.
Study NCT05259475 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle Advice
Description: Maintain a weekly healthy diet and regular exercise.
Study NCT05259475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Intervention
Description: Calorie-restricted meals (lunch and dinner)
Study NCT05259475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OCFA Meal-Based Diet-Intervention
Description: OCFA-containing food product
Study NCT00013052 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer led classes. Led by trained veterans with a chronic disease.
Study NCT06002152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of 0.25% bupivacaine on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
Study NCT06002152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of saline on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
Study NCT05974306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implantable loop recorder
Description: Implantation of an implantable loop recorder
Study NCT05240144 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: IHG
Description: Isometric handgrip exercises will be performed for 4 x 2 min with the frequency of 3 days per week for a period of 6 weeks.
Study NCT05240144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IHG
Description: Isometric handgrip exercises will be performed for 4 x 2 min with the frequency of 3 days per week for a period of 6 weeks.
Study NCT06208072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan 150mg
Description: Irbesartan group will be treated with Irbesartan 150mg once daily for a total of 8 weeks.
Study NCT06208072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone 25 mg
Description: Eplerenone group will be treated with Eplerenone 25mg twice daily for a total of 8 weeks
Study NCT06333990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate
Description: Quetiapine is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia, bipolar disorder, and as an adjunct to treat major depression. It has a broad spectrum of actions at dopaminergic (D1, D2, D3 and D4), serotonergic (5-HT2A, 5-HT2C and 5-HT7), adrenergic (α1), histaminic (H1) and muscarinic (mACh), and partial agonist at 5-HT1A receptors.
Study NCT06333990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Standard of care psychotropic medications for treatment of patients with mTBI.
Study NCT05743192 — intervention group
Intervention type: OTHER
Intervention: Stop performing an antibiotic susceptibility test
Description: Intervention = Stop performing an antibiotic susceptibility test for enterococcus faecalis in urine cultures. It defines two groups : one before and one after the intervention
Study NCT05457543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adult
Description: Investigational use of a novel liver function diagnostic test that involves a paper-based test device and a smartphone application.
Study NCT05240144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercises
Description: Aerobic exercise according to the American College of Sports Medicine (ACSM) guidelines that provide the specific criteria as 50 minutes exercises for 3 days a week for a period of 6 weeks.
Study NCT05240144 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aerobic exercises
Description: Aerobic exercise according to the American College of Sports Medicine (ACSM) guidelines that provide the specific criteria as 50 minutes exercises for 3 days a week for a period of 6 weeks.
Study NCT05240144 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IHG
Description: Isometric handgrip exercises will be performed in 4 sets for 2 min at 5% MVC on both hands with the frequency of 3 days per week for a total 6-week period
Study NCT04876183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selfapy for Binge Eating Disorder
Description: Web-based intervention for Binge Eating Disorder with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
Study NCT05382728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591
Description: The dose of TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT05382728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo Osimertinib
Description: The dose of placebo Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT05334329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antineoplastic Immune Cell
Description: Given COH06 IV
Study NCT05334329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05334329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT05334329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05334329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT05382728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT05382728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo TY-9591
Description: The dose of placebo TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT05502289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST LENS
Description: DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
Study NCT05502289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL LENS
Description: PRECISION1™ for Astigmatism Contact Lenses (P1fA)
Study NCT06037876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVM (200 µg/kg) + ALB (400 mg)
Description: World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.
Study NCT06037876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALB (400mg)
Description: Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO